Latest Capital Raises News

Microba Life Sciences reported a 30% increase in revenue to $15.7 million for FY25, driven by strong growth in its core microbiome diagnostic products and successful UK market expansion. Despite narrowing its net loss to $14.9 million, the company is focused on scaling diagnostics adoption and achieving break-even in FY26.

Hazer Group Limited reported a 124% surge in revenues to $8.5 million for FY25, driven by government grants, while cutting its net loss by 60%. The company advanced its proprietary methane pyrolysis technology, secured a strategic alliance with KBR, and made progress on key projects in Canada and Japan.

Kali Metals Limited has successfully completed a placement raising approximately A$1.2 million through the issuance of new shares at A$0.14 each, reinforcing its capital position amid ongoing exploration efforts.

Arafura Rare Earths has successfully completed the first tranche of its A$80 million capital raising, issuing 369.6 million new shares and securing A$70.2 million before costs. The remaining tranche awaits shareholder approval.

WAM Active Limited reported a robust 26.4% increase in its investment portfolio for FY2025, significantly outperforming key benchmarks, while maintaining its fully franked dividend at 6.0 cents per share.

Elanor Commercial Property Fund reported a statutory loss for FY25 but delivered a 6.9% rise in Funds from Operations, while rejecting an unsolicited takeover offer from the Lederer Group.

Elanor Commercial Property Fund reported a solid FY25 with strong income and portfolio stability, while rejecting an unsolicited takeover bid from Lederer Group.

Elanor Commercial Property Fund reported a $5.4 million statutory loss for FY25 despite a slight increase in Funds from Operations, while navigating a strategic capital raise and an unsolicited takeover offer from the Lederer Group.

QX Resources has acquired 100% of the Madaba Uranium Project in Tanzania, a site with promising historical uranium grades, and is raising $2.3 million to advance exploration and development.

High-Tech Metals Limited has successfully completed the placement of the shortfall from its recent entitlement issue, raising approximately $1 million before costs through new shares and listed options.

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.

Decidr AI Industries has locked in a $3.9 million underwriting agreement with Morgans Corporate Limited to back the exercise of listed options expiring this month, providing crucial funding ahead of its DecidrOS Beta release.